Zobrazeno 1 - 10
of 13 902
pro vyhledávání: ''
Autor:
Lars Bullinger, Jörg Westermann
Publikováno v:
Seminars in Cancer Biology. 84:153-169
Myeloid malignancies have always been at the forefront of an improved understanding of the molecular pathogenesis of cancer. In accordance, over the last years, basic research focusing on the aberrations underlying malignant transformation of myeloid
Autor:
Prakash Priyadarshi Praharaj, Debasna P. Panigrahi, Bishnu Prasad Behera, Kewal Kumar Mahapatra, Shankargouda Patil, Amruta Singh, Rohan Dhiman, Srimanta Patra, Soumya Ranjan Mishra, Chandra Sekhar Bhol, Sujit K. Bhutia, Samir Kumar Patra
Publikováno v:
Seminars in Cancer Biology. 83:399-412
Tumour-promoting inflammation is a critical hallmark in cancer development, and inflammasomes are well-known regulators of inflammatory processes within the tumour microenvironment. Different inflammasome components along with the adaptor, apoptosis-
Autor:
Wissam Zam, Lina Ali
Publikováno v:
Current Reviews in Clinical and Experimental Pharmacology. 17:103-113
Background: Immunotherapy drugs, known as immune checkpoint inhibitors (ICIs), work by blocking checkpoint proteins from binding with their partner proteins. The two main pathways that are specifically targeted in clinical practice are cytotoxic T-ly
Publikováno v:
Neuroscientist
Both sepsis and treatment of cancer with chemotherapy are known to cause neurologic dysfunction. The primary defects seen in both groups of patients are neuropathy and encephalopathy; the underlying mechanisms are poorly understood. Analysis of precl
Autor:
Sunil J. Advani, Hyunho Yoon, Rowan Ustoy, Mayra Yebra, Vipul R. Sheth, Sudeep Banerjee, Michael Heinrich, Christian M. Metallo, Joseph A. Aguilera, Sangkyu Noh, Scott M. Lippman, Razelle Kurzrock, Chih-Min Tang, Olivier Harismendy, Paul T. Fanta, Adam M. Burgoyne, Avi Kumar, Thekla Cordes, Shruti Bhargava, Sam Li, Jason K. Sicklick, Christopher L. Corless
Publikováno v:
Clin Cancer Res
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 28, iss 1
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 28, iss 1
Purpose: Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the gastrointestinal tract, with mutant succinate dehydrogenase (SDH) subunits (A–D) comprising less than 7.5% (i.e., 150–200/year) of new cases annually in the United S
Autor:
Yiran Zhang, Satimai Aniwan, A Weiss, Gursimran Kochhar, Sunanda V. Kane, Bo Shen, Matthew Bohm, Siddharth Singh, Eugenia Shmidt, Jean-Frederic Colombel, Corey A. Siegel, David Faleck, Edward V. Loftus, James P. Campbell, Mahmoud A. Rahal, Siri Kadire, Ronghui Xu, William J. Sandborn, David Hudesman, Arun Swaminath, Joseph Meserve, Robert Hirten, Vipul Jairath, Ryan C. Ungaro, Bruce E. Sands, Karen Lasch, Jenna L. Koliani-Pace, Brigid S. Boland, Parambir S. Dulai, Dana J. Lukin, Shreya Chablaney, Monika Fischer, Adam Winters, Gloria Tran, Shannon Chang, Sashidhar Varma
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 20, iss 1
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 20, iss 1
Background & Aims We aimed to compare safety and effectiveness of vedolizumab to tumor necrosis factor (TNF)-antagonist therapy in ulcerative colitis in routine practice. Methods A multicenter, retrospective, observational cohort study (May 2014 to D
Publikováno v:
Biomedical Journal. 44:694-708
Background Pancreatic cancer is one of the most notorious cancers and is known for its highly invasive characteristics, drug resistance, and metastatic progression. Unfortunately, resistance towards gemcitabine develops in many with advanced pancreat
Autor:
Bei Zhang, Wenzhuo He, Dongsheng Zhang, Xiuxing Chen, Fenghua Wang, Yixing Wang, Qi Quan, Guifang Guo
Publikováno v:
Current Oncology, Vol 28, Iss 23, Pp 209-219 (2021)
Current Oncology
Volume 28
Issue 1
Pages 23-219
Current Oncology
Volume 28
Issue 1
Pages 23-219
Background: There have not been any head-to-head prospective studies to compare the effects of different chemotherapy regimens as first-line treatments for unresectable pancreatic cancer (UPC). We aimed to compare the effectiveness of nab-paclitaxel
Autor:
Abhinav Zawar, Suresh Kumar Bondili, Manju Sengar, Lingaraj Nayak, Navin Khattry, Jayashree Thorat, Pradeep Ventrapati, Hashmukh Jain, Anant Gokarn, Sachin Punatar, Bhausaheb Bagal, Avinash Bonda
Publikováno v:
JCO Global Oncology
PURPOSE The prognosis of relapsed and refractory multiple myeloma (RRMM) that is refractory to bortezomib and lenalidomide is very poor wherein the median survival is between 3 and 9 months. We did this retrospective analysis to study the pattern of
Publikováno v:
Current Oncology, Vol 28, Iss 12, Pp 94-97 (2021)
Paediatrics Publications
Current Oncology
Paediatrics Publications
Current Oncology
5-fluorouracil (5-FU) and its pro-drug capecitabine are widely used anticancer agents. Most 5-FU catabolism is dependent on dihydropyrimidine dehydrogenase (DPD) encoded by the DPYD gene, and DPYD variants that reduce DPD function increase 5-FU toxic